eular 2011 updates
DESCRIPTION
Eular 2011TRANSCRIPT
BMS
India
EULAR 2011-RA updates
By A.Arputha Selvaraj APMP IIM Calcutta
Agenda
We will discuss updates from EULAR 2011 about:
1. Diagnosis of RA
2. RA remission
3. Early RA
4. Safety of medications in RA
5. Imaging in RA
6. Other updates in RA
BMS
India
Diagnosis
BMS
India
BMS
India
2010 ACR/EULAR RA criteria in clinical practice: Prediction of clinical RA & distribution of patients with early UA
• New ACR/EULAR criteria → predicts risk of RA (early)
- Tree format or scoring system → ≥ 6 points = RA
• NOR-VEAC: (SJC ≥1 with ≤16 weeks duration, 18-75 ys)
• 128/343 definite RA by both versions new criteria
• 82/83 (98.8%) >10 joints = RA vs 3/111 (2.7%) 2-10 joints
• 57/60 (95%) ↑ ACPA and/or RF = RA
• Sensitivity 85.9%; specificity 80.5%; LR+ 4.4, LR- 0.18; area under the ROC curve (95% CI) was 0.92 (0.89-0.95)
Criteria performed well in predicting clinical RA, particularly in seropositive patients
Mjaavatten MD, et al. EULAR 2011, London, #SAT0373
BMS
India
BMS
India
Comparison of 1987 & 2010 classification criteria for RA in patients with early arthritis
• 253 pts with ≥1 swollen joint for ≥4 wks; symptoms < 1 y
• RF+ 34.4% pts
• CCP+ 28.6% pts
• Gold std: pts Dx after 2 ys f/u
• Estimate sensitivity, specificity, PPV, NPV, LR+ &
LR-
RA diagnosis • 108 pts (42.7%) with 2010 criteria
• 114 pts (45.1%) with 1987 criteria
Sens. (%)
Spec. (%)
PPV (%)
NPV (%)
LR+
LR-
2010 1987
80 86
81.7 81.7
74.1 75.4
86.2 89.9
4.37 4.7
0.245 0.171
LR = likelihood ratio
No relevant differences in RA diagnosis using 1987 or 2010 criteria
Fernandez-Ortiz AM, et al. EULAR 2011, London, #SAT0396
BMS
India
BMS
India
Remission
BMS
India
BMS
India
BMS
India
CATCH: Remission prevalence in early RA -new criteria vs other criteria
RF+/ Bio CCP+ (n) %
100 Mean CRP (mg/dL) 80
% remission at 12 months
DAS28<2.8 56/62 7 0.33 60 53 DAS28<2.0 55/61 7 0.26
SDAI<3.3 59/64 9 0.32
CDAI<2.8 58/64 10 0.38
ACR/EULAR 54/65 8 0.27
40
20
0
36 27 25 22
• ACR/EULAR criteria agrees with SDAI (k=0.75) & CDAI (k=0.73)
• Fair agreement with DAS28<2.6 (k=0.32) & DAS28<2.0 (k=0.35)
All remission is not the same1,2
1. Kuriya B, et al. EULAR 2011, London, #SAT0405; 2. Bernard M, et al. Ibid, #OP0027
BMS
India
BMS
India
Utility of 2011 ACR/EULAR 2011 remission criteria
• US VA and community practice cohort study1
- 1,341 VA patients / 9,700 visits (91% men)
– 1,168 community practice patients / 6,362 visits (28% men)
– Remission (US VA / community practice): • Cross-sectional: 8.9% / 8.3%
• Cumulative: 24.4% / 19.0% over mean of 2.2 ys
• 1.9 - 4.6% patients met remission at ≥2 visits
• Among all patients, <3% had remission lasting 2 ys
• Non-inclusion of feet may overestimate remission3
• Patients in ACR/EULAR remission have function capacity = to normal4
Remission is uncommon in the clinic, especially long term
1. Michaud K, et al. EULAR 2011, London, #FRI0333; 2. Vermeer M, et al. Ibid, #OP0311; 3. Bakker MF, et al. Ibid, #SAT0376; 4. Listing J, et al. Ibid, #THU0351
BMS
India
BMS
India
BRASS: Radiological progression in remission by new ACR/EULAR criteria vs other criteria
DAS BL rem. TSS mean ann. change % w/ prog. LR+ good outcome
DAS28(CRP)<2.6 106 0.93 (median 0) 30% 1.5
SDAI<3.3 37 0.65 (median 0) 24% 2.1
CDAI<2.8 26 0.37 (median 0) 19% 2.8
ACR/EULAR≤1 30 1.08 (median 0) 20% 2.6
ΔTSS in pts assessed to be in remission by DAS28, CDAI, ACR/EULAR15
10 DAS28 2.6
CDAI 5 ACR/EULAR
0
0 10 20 30 40 50 60 70 80 90 100% patients
New ACR/EULAR criteria performed similarly to established criteria
Lillegraven S, et al. EULAR 2011, London, #SAT0398
BMS
India
BMS
India
Power Doppler ultrasound is useful in determining true remission
• 109 RA pts on TNFi in DAS28 remission for 6 months
• 49.5% PDUS- / 50.4% PDUS+
• No PD signal, no radiological progression
• 29.1% with PD signal had radiological progression
Image courtesy of AF Wells, MD, PhD
• Absence of PD signal guarantees arrest of radiologic progression, whereas pts with PD signal are at risk for progression despite treatment with TNFi
• This risk increases with higher PD grades
PDUS may be useful in evaluating pts considered to be in remission
Raffeiner B, et al. EULAR 2011, London, #OP0029
BMS
India
BMS
India
Early RA
BMS
India
BMS
India
T2T strategies in early RA: OPTIMA Study design
• MTX-naive pts ≥18 ys with RA <1 y & active disease (DAS28>3.2, ESR ≥28 mm/h or CRP ≥1.5 mg/dL), and either >1 erosions, RF+ or anti-CCP+
n=466**
ADA 40 mg EOW+MTX *
n=460**
MTX*
n=207
Yes DAS28
<3.2 No
n=259
n=112 Yes
DAS28 <3.2
No
MTX n=102
ADA 40 mg EOW+MTX n=105
OL ADA 40 mg EOW+MTX
MTX
OL ADA 40 mg EOW+MTX
ARM 1 ADA+MTX / MTX
ARM 2 Sustained ADA+MTX
ARM 3 Primary ADA+MTX IR/ADA+MTX efficacy
outcome†
ARM 4 Sustained MTX
† DAS28 <3.2
and mTSS <0.5 ARM 5
n=348 MTX IR/ADA+MTX at Week 78
0 w PERIOD 1 26 w
PERIOD 2 78 w
* MTX titrated to 20 mg/wk by Wk 8; ** Completed study period
Smolen J, et al. EULAR 2011, London, #THU0243
BMS
India
BMS
India
OPTIMA: ADA+MTX / MTX vs sustained ADA+MTX
ADA+MTX / MTX (n=88)
ACR
Sustained ADA+MTX (n=94)
Radiographic prog: % pts 100 ACR20
100 89.0 88.0 89.0
ACR50 80
ACR70
60
40 26 30 34 38 42 46 50 54 58 62 66 70 74 78
Weeks
80 89.0
60
40
20
0 26
85.0 81.0
52
78
Weeks For many early RA patients in LDA on TNFi/MTX, TNFi can be withdrawn for a year; some patients may need continued treatment
Smolen J, et al. EULAR 2011, London, #THU0243
BMS
India
BMS
India
OPTIMA: Sustained ADA+MTX vs sustained MTX at Week 78
Sustained ADA+MTX (n=94) Sustained MTX (n=98)
100
80
60
40
20
0
*
LDAS + mTSS 0.5 from
BL
* 100 *
75
50
25
0 ACR20 ACR50 ACR70
*P<0.05: ADA+MTX vs • sustained MTX
X-ray progression 89 88 89
82 82 78
26 52 78
44% Arm 2 v 24% Arm 1 achieved LDA during phase 1
Although both groups did well in LDA; patients on TNFi/ MTX did slightlybetter than those on MTX alone
N Smolen J, et al. EULAR 2011, Lon don, #THU0243
BMS
India
BMS
India
Is there a window of opportunity in early RA?
• 8 year f/u of PREMIER: DBPCRCT of ADA, MTX, ADA + MTX early RA (<3 ys)1
• After 2 ys all pts were on ADA; MTX could be added (30-35% did)
100
80
60
40
71.3 58.4
49.5
MTX (n=89)
43.8
28.3
ADA (n=92) MTX/ADA (n=89)
50.6
28.7 16.9 20 11.8
0 DAS28 <2.6 SDAI ≤ 3.3 DAS28<2.6 + HAQ ≤ 0.5 +
ΔTSS ≤ 0.5
• Group 5 from OPTIMA (MTX/IR MTX/ADA at 6 months): comparable response to MTX/ADA from the start2
Early aggressive therapy may achieve long-term benefit in early RA
Breedveld F, et al. EULAR 2011, London, #THU0230
BMS
India
BMS
India
Early addition of low-dose prednisone to tight control: CAMERA II
• DB study, 236 early RA pts (<1 y)
• MTX + PBO vs MTX + Pred 10 mg QD
- Pred continued for 2 ys
- Evaluated once a month
• ADA added for failure to reach target
• At 2 years:
- Lower disease activity and disability in Pred group
- No ↑ DM, infections or fractures
- Lower LFTs and ADA in Pred group
80 P=0.09 MTX+Pred
70 MTX 60
50
40 P<0.001
30
20
10
0 % REM % on TNFi % AE
Low-dose prednisone at start of Tx leads to better control and noincrease in toxicity
Bakker MF, et al. EULAR 2011, London, #OP0138
BMS
India
BMS
India
Smokers have no “window of opportunity”
• Data from BARFOT
- 12 mo f/u in 1,587 early RA patients
• Pts with early disease (<3 mos) show significant improvement, each month, when treated
• Smokers did not show this trend
Change in DAS28 over time
-0.05 Non smoker Current smoker
-1.50
-2.50
-3.50
2 - 12 months 2 - 12 months
Smokers are less likely to respond to early treatment of RA
Söderlin M, et al. EULAR 2011, London, #SAT0372
BMS
India
BMS
India
Stopping TNFi in RA
• Japanese study: stop ADA if DAS28≤2.6 x 6 mos1
- Mean RA duration 8 ys
- Stable MTX (mean dose 12.5 mg)
- ADA for ≥1 y
• 40/163 pts stopped ADA: data on 27 pts at 24 weeks- 16/27 in DAS remission; mean DAS28 = 1.8 at entry
- 3/27 LDAS
- 8/27 flared; mean DAS28 = 2.2 at entry
• 90% of DAS28≤1.9 did not flare at 6 months
TNFi may be stopped in patients who attain DAS remission for6 months; especially with very low DAS28
Tanaka Y, et al. EULAR 2011, London, #OP0154
BMS
India
BMS
India
Treat-to-Target in routine clinical care
• 2 studies using DAS28 remission as target in “standard therapy”
• No preset order of med use
• DAS28 remission in 26.5%1 & 32%2
• ACR/EULAR remission in only 8.6%1
- Is ACR/EULAR remission too strict?
• Use of most recent ESR/CRP (up to 3 mos from visit) does not effect validity of DAS283
DAS28 median
Remission %
LDAS only %
LDAS + remission % HAQ median
*P<0.001
Baseline Year 3
4.0 3.1*
22.8 32*
12.5 19.6*
35.3 51.6*
1.35 1.25
Treating to a target feasible in routine clinical care using currently available therapies; results in high rates of remission and LDAS
1. Favarato MH, et al. EULAR 2011, London, #SAT0374; 2. Gullick NJ, et al. Ibid, #SAT0209; 3. Brode S, et al. Ibid, #SAT0202
BMS
India
BMS
India
REALISTIC study: CZP in DMARD-IR and TNFi-IR RA pts
• 1,063 pts, 37.6% with TNFi exposure; 20.3% received CZP as monotherapy
100 CZP (n=320) P<0.001 Control (n=80)
80
60
40
20
0
P<0.01
47.2
27.5
53.5
25
47.6
20.8
51.9 52.3
27.8 25
53.5 46.7 48.3
30.6 25
12.5
Prior TNFi No prior 0 1 ≥2 0 1 2TNFi
ACR20 No. of concomitant No. of prior TNFiDMARDS
CZP shows efficacy after TNFi exposure and as monotherapy in RA
Weinblatt ME, et al. EULAR 2011, London, #FRI0214
BMS India
BMS
India
No mortality differences between TNF inhibitors
2 • ARTIS database (Sweden); N=6,322
1.5
• Compared mortality Ref1
between ADA, ETN and IFX
0.5
• 211 deaths (3.3%)
0 ETN ADA IFX
(n=2,686) (n=1,609) (n=2,027)
No difference in mortality regardless of adjustments for co-factorsor other modeling techniques
Simard J, et al. EULAR 2011, London, #OP0158
BMS
India
BMS
India
Safety
BMS
India
BMS
India
Effect of treatment on mortality in RA
• BSRBR RA pts, DAS28>4.2
• >5 y f/u; ETN vs DMARDs
• ETN: higher disease activity / severity, less comorbidity
• Mortality: adj. HR 0.59 (0.44-0.78) 0.786 (0.57-1.08): depends on time censure modeling
• Caveats: patients excluded if switched to other biologics
N (pt-ys)
Mean f/u
Age
RA duration
HAQ
Deaths
Deaths/1000 pt-ys
*P<0.001
ETN pts DMARD controls
3,470 1,365 (14,382) (5,583)
4.1 ys 4.1 ys
55.4 ys 59.5 ys*
13.6 ys 9.6 ys*
2.1 1.7
188 127
13.1 22.2
Mortality not elevated; may be lower with TNFi therapy in RA
Emery P, et al. EULAR 2011, London, #LB0007
BMS
India
BMS
India
CV risk in RA is independent of disease duration but varies with disease activity
• EULAR identifies RA disease duration >10 ys as CV risk factor
However:
• 855 pts (6,388 pt-ys) → 90 1st CV events: MI, CVA, heart failure
• CV risk ↓↓ only with DAS28 <2.9 over time vs other groups (P=0.04)
• No difference in survival
Cumulative survival for different DAS28 levels (< 10 ys disease duration)
1.0
0.9
0.8 Low (<2.9) Low-medium (<2.9-3.6) Medium-high 3.6-4.3) High (>4.3) 0.7
distribution between disease 0.0
duration < or > 10 ys 5.0 10.0 15.0 20.0 25.0
Time to event (years)
RA duration does not aggravate CV risk over time; CV risk not ↑ after 10 ys of disease duration vs 1st 10 ys; CV risk ↓↓ lower only with DAS28 <2.9
Arts EEA, et al. EULAR 2011, London, #OP0161
BMS
India
BMS
India
Cancer risk and RA treatments: Two studies
8
7
6
5
4
3
2
1
0
BSRBR - DMARD1
(n=3,727; 148 w/cancer)
Lym
ph
NHL Melan
Myelo Lung
All excl. NMSC
Solid B
reast Colorect
DANBIO - TNFi2
• 13,699 pts; 5,598 on TNFi
• Cancer in 313
• RR: 1.05 (CI 95% 0.82-1.34) vs DMARD
• No increase in any CA
- Including NMSC & non-Hodgkins
- No effect of duration of Tx
- Also true for PsA & “other” arthritis
DMARD use is associated with 50% increase in all cancers
1. Mercer LK, et al. EULAR 2011, London, #FRI0338; 2. Dreyer L, et al. Ibid, #FRI0203
BMS
India
BMS
India
SIE with TNFi in RA: DREAM and GISEA registries
10 DREAM registry1 10 GISEA registry2
9 (N=2,157, since 2003) (N=2,769)
8 87
6 65
4 43
2 2
1
0 0ETN ADA IFX ETN ADA IFX
• Adj HR: 1.02 ADA vs IFX; 0.59 vs mAb • Sig diff in SI risk in ADA, ETN & IFX• IFX pts tended to have worse prognosis pts (P<0.0001)
TNFi is associated with small but significant risk of SI
1. van Dartel S, et al. EULAR 2011, London, #FRI0222;2. Atzeni F, et al. Ibid, #THU0229
BMS
India
BMS
India
Risk factors associated with GI perforation in RA patients
RR of GI perforation during f/u (adjusted results) HR (95% CI)
Diverticulitis
Diverticulosis w/o diverticulitis Other DMARDs w/ glucocorticoids
Glucocorticoids w/o any DMARD MTX w/ glucocorticoids
Biologics w/ glucocorticoids Biologics w/o glucocorticoids Other DMARDs w/o glucocorticoids No DMARDs or glucocorticoid
NSAID Baseline CCI
Age 65+ Age 40-64
Female Urban
CCI = Charlson Comorbidity index 0 1 2 3 4 11 13 15 17 19
GI perforation is rare and increases with age, steroids, andespecially history of diverticulitis; NSAIDs impose a minor risk
Curtis J, et al. EULAR 2011, London, #OP0159
BMS
India
BMS
India
Quantiferon (QTF) vs TST performance in TNFi-treated patients
• 150 AS/RA pts screened by Hx, CXR, IGRA, TST
• TST more frequently positive than QFT
• Clinical suspicion of LTBI in 21 patients (based on LTBI risk factors)
• 14 (9.3%) QTF+ & 67 (45%) TST+
- 56% agreement: TST + QTF (k=0.1; P=0.01)
• 17% had indeterminate results - Assoc. w/ elderly, DMARD, pred. use
56% TST+ QFT+ 45% 9.3%
- Results turn negative after TNFi
• 6 QFT+ pts Tx for LTBI (INH/RIF x3 mo) - F/u QFT was negative in 4 pts
Assoc. w/ LTBI risk factors
21% 50% (RR=2.5) (RR=4.8)
QFT+ more strongly associated with LTBI risk factors Indeterminates may convert to negative with 6 mos of TNFi
Cabantous L, et al. EULAR 2011, London, #THU0249
BMS
India
BMS
India
BMS
India
Imaging
BMS
India
BMS
India
Which comes first: JSN vs JE? PREMIER, MTX-naive, early RA
3
2
1
0 JE All
@Wk26 Swelling Wks 26-52
MTX vs MTX vs ADA ADA+MTX
• 226/17,644 (1.3%) evaluable joints lacked JSN at Wk 26 but had JSN progression by Wk 52
- 49 (21.7%) JE-/SJ-
– 44 (19.5%) JE-/SJ+
– 66 (29.2%) JE+/SJ-
– 67 (29.6%) JE+/SJ+
• Both JE & swelling assoc. with the onset of JSN at Week 52
Erosions contribute to JSN: JSN is the main driver of functional disability
Landewe R, et al. EULAR 2011, London, #FRI0209; Aletaha D, et al. Ann Rheum Dis. 2011;70:733-9; Landewe R, et al. Ann Rheum Dis. 2011;70:717-8
BMS
India
BMS
India
Do NSAIDs affect US activity in RA patients?
N=58 Stopped Continued P-valueNSAID NSAID
SJC +1.5 -1.0 <0.001
TJC +2.5 0 <0.001
GSUS +9.5 +1.0 <0.001
PDUS +4 0 <0.001
GSUS score >0 4 joints 1 joint <0.001
PDUS score >0 2 joints 0 joints 0.005
NSAIDs may decrease both GSUS and PDUS signal resulting inlower scores despite ongoing disease activity; considerationshould be given to NSAID effect in designing US clinical studies
Zayat AS, et al. EULAR 2011, London, #OP0242
BMS
India
BMS
India
Early reductions in synovitis & osteitis with TCZ are maintained through Week 52: ACT-RAY MRI substudy
• RA pts (n=63) on stable MTX randomized to MTX or PBO + TCZ 8 mg/kg IV every 4 weeks
• Decreases in synovitis & osteitis at Week 12 sustained at Week 52
Synovitis
20 15
10
Osteitis Erosions
*P<0.05 vs BL
* • No significant change in mean erosions over 52 weeks
• No patients developed new regions of synovitis
5
0
*
BL Week 12
* *
Week 52
Early reduction of synovitis & osteitis by MRI with TCZmaintained through 1 year
Troum O, et al. EULAR 2011, London, #SAT0282
BMS
India
BMS
India
Xiralite vs ultrasound and MRI
• Fluorescence optical imaging (IV indocyanine green) to assess inflammation of the hand
• Information collected at various phases post-injection
• Early-phase imaging showed good agreement with clinical exam, PDUS, MRI, and less with GSUS
• 92% (53/57) swollen joints and 94% (63/67) joints with MRI synovitis showed positive findings
• Limitations: thick skin, palmar tenosynovitis
Comparison Method Sensitivity Specificity Clinical exam 58% 90% Xiralite P1 34% 95% Xiralite P2 83% 69% Xiralite P3 60% 92%
Fluorescence optical imaging with Xiralite system sensitive in detecting early inflammation
Werner, et al. EULAR 2011, London, #FRI0048; Werner, et al. Ibid, #SAT0101
BMS
India
BMS
India
JIA
BMS
India
BMS
India
Switching in JIA
• In SoJIA (German JIA Registry, 20
N=1,345), switching to 2nd 15
TNFi or ABA was 10 unsuccessful1
5
• In PolyJIA switching to a 2nd 0
TNFi gave favorable results1
• In some PolyJIA pts, switching 40
to CZP may also be effective2 30
20
Switching from one biologic to 10
another may be effective, but SoJIA patients respond differently than 0
PolyJIA patients
1. Horneff G, et al. EULAR 2011, London, #FRI0176;
Systemic JIA: Last response
0 response PedACR30 PedACR50 PedACR70
ETN IFX ADA ANA TCZ ABA n=26 n=1 n=4 n=21 n=2 n=2
Poly JIA: Last response
ETN IFX ADA ANA TCZ ABA n=57 n=10 n=43 n=4 n=4 n=5
2. Tzaribachev N, et al. Ibid, #FRI0194
BMS
India
BMS
India
TENDER: TCZ effective in persistent SoJIA
• 12 wk DBPCRT followed by OL Tx
• TCZ 8 (>30 kg) or 12 (<30 kg) mg/kg
• All patients received OL TCZ 8 or 12 mg/kg in part 2
• Primary outcome: ACR JIA 30 + no fever
• Week 12 response maintained at Week 52; 52% pts able to D/C steroids
• Safety: 15 SIEs; 1 infusion reaction; 2 grade IV neutropenias; 3 deaths (1 MVA; 1 pneumothorax; 1 unknown)
ACR30+no fever ACR70 ACR90
100 Week 12 Week 52
80
60
40
20
0 Control TCZ TCZ (n=37) (n=75) (n=88)
One year of TCZ is highly effective and generally welltolerated in patients with SoJIA
De Benedetti F, et al. EULAR 2011, London, #OP0006
BMS
India
BMS
India
Miscellaneous
BMS
India
BMS
India
Work outcomes
• GLM+MTX vs MTX ↑ employability by 0.96 ys (female)/0.87 ys (males)1
• RA imposes a burden similar to DM justifying cost of treatment2
- Incremental cost (RA vs DM )
• $5,212 vs $3,698 vs
$4,014
– Incremental days absent • 3.58 vs 2.73 vs 6.42
• Young patients more likely to consider themselves a burden3
% patients unemployable at
BL and
40 employable at Week 241 33*
30 *P<0.05
20 15
10
0 Placebo + MTX Combined GLM +
MTX
RA imposes a significant burden to both employers and caregivers Treatment with TNFi + MTX can improve employability
1. Han C, et al. EULAR 2011, London, #THU0045; 2. Brook RA, et al. Ibid, #THU0031; 3. Bergman M, et al. Ibid, #FRI0241
BMS
India
BMS
India
Alcohol intake and inflammatory polyarthritis (IP) in Norfolk Arthritis Register (NOAR)
1.3 ↓risk for every 1 unit/day consumed
(hazard ratio)
1.0
0.8
0.7
0.6
0.5 IP RA Sero+ IP
• 184 incident IP patients among 25,639 population
• 138 fulfilled 1987 RA criteria
• Smoking ↑ risk RA & IP
• EtOH 16% ↓ risk/unit consumed
HR (95% CI) ↑ risk IP in
Fully adj. age, gender , smoking, BMI, diabetes, social class
Fully adj. age, gender , smoking, BMI, diabetes, social class, parity & breastfeeding
smokers ↓ risk RA in smokers
Alcohol intake ↓ risk of IP
1.70 (1.12-2.57)
1.68 (1.03-2.73)
0.84 (0.72-0.97)
Alcohol consistently shown to decrease risk of IP and RA andnegates effect of smoking
Lahiri M, et al. EULAR 2011, London, #OP0025
BMS
India
BMS
India
Sexual dysfunction in RA
• 231 RA patients1
- 91 male/140 female
• Among men
RA has a significant impact on my sex life2
100% 72% All
- 49/91 (53.8%) reported ED • 18/49 mild • 16/49 mild to moderate • 13/49 moderate • 2/49 severe
• Among women - 67/150 (44.6%) reported
sexual dysfunction
- Dyspareunia due to decrease lubrication most common complaint
1. El Miedany Y, et al. EULAR 2011, London, #SAT0232; 2. Sharma P et al. Ibid, #SAT0213
80% 67% 65% 60%
40%
20%
0%
Sexual dysfunction is common in RA; strong association between sexual dysfunction and cardiovascular disease
Men
Women
BMS
India
BMS
India
Patient-reported outcome measures
• Japan1 & Finland2 - pts evaluated with RAPID3, CDAI and DAS28
• Correlation:1
- RAPID3 vs DAS28 r=0.66
- RAPID 3 vs CDAI r=0.78
• Remission agreement good between RAPID3, CDAI ACR/EULAR and DAS281
• Any measure using 3 or 4 of ACR core data set will measure disease activity well3
5
4
3
2
1
0
-1
-2
-3
-4
-5 -5
Standard change RAPID3 vs CDAI2
-4 -3 -2 -1 0 1 2 3 4 5 Standard change of RAPID3
RAPID3 requires minimal input from physicians and can serve as a useful alternative to other measures in clinical practice
1. Seto Y, et al. EULAR 2011, London, #SAT0409; 2. Sokka T, et al. Ibid, #FRI0280; 3. Bergman M, et al. Ibid, #THU0300
BMS
India
BMS
India
Utility of a biomarker test in RA
• Multi-biomarker disease activity (MBDA; sold as VECTRA™) test for RA
• 126 pts from BeSt
• Serum at BL and 1 y; correlated with ΔSHS (BL1, 2 ys)
Biomarker test results correlate with outcomes, including X-ray, as do other measures and markers
Allaart C, et al. EULAR 2011, London, #THU0319 Weinblatt ME, et al. Ibid, #THU0339
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Predictors of X-ray progression Year 1 to 2
BMS
India
BMS
India
Anakinra as first-line biologic: Results from real-world Italian GISEA retrospective registry
• RA patients starting biologics from 14 centers in Italy
• 129 starting anakinra matched 1:4 with 515 starting ADA or ETN
- Matched age, sex, disease activity, year of treatment (anakinra patients had increased disease duration, higher HAQ, higher PtG)
• Results: remission at 12 months
- Anakinra = 18.6%; TNFi = 26%
- TNFi patients had significantly lower baseline disease duration, pain, global health and HAQ scores
- Univariate analysis suggests that longer disease duration and higher HAQ score may account for difference in remission rates
Anakinra remission rates somewhat lower than TNFi, but still remains proven biologic option in patients with active RA
Sfriso P, et al. EULAR 2011, London, #SAT0283
BMS
India
BMS
India
Periodontal disease (PD) and RA
Severe PD occurs 10-15% RA pts
• Dutch study:1 98 RA pts assessed with PD Screening and RA activity
- 50% had PD (18% severe) – More RA smokers had PD (P=0.01); - PD assoc. w/ higher DAS28 & CRP
P=0.047
• Brazilian study:2 18 pts had dental exams pre/post TNFi x 6 mo
- Mostly IFX: 15 (83%)
- Significant response to TNFi w/o change in PD status
TJC SJC DAS28 CRP
15
10 6
54 w/o PD w/ PD
0 2 BL 6 mo BL 6 mo
– PD+ (8/18): no improvement after0 6 mos of TNFi treatment
1-2 3-6PD score - PD- (10/18): respond best to TNFi
PD prevalent in RA; TNFi treatment does not affect PD, but patients withPD may have blunted response to TNFi
1. De Smit M, et al. EULAR2011, London, #THU0289;2. Savioli C, et al. Ibid, #SAT0138
BMS
India
BMS
India
Tofacitinib [Tofa] (oral JAK 3,1,2 inhibitor) in combination with traditional DMARDs (ORAL Sync)
• 792 active RA: DMARD-IR (4:4:1:1)
• PBO for 6 months (rescue at Mo 3) vs Tofa 5 or 10 mg BID
• Multinational study:
- 22% North America
– 8.3% South America
– 28.3% Europe (85% Eastern Europe)
– 41.4% Rest of world (28% China)
• Co-1° EP
- ACR20 (NRI), Mo 6
- HAQ-DI ∆ from BL, Mo 3
- DAS28-4(ESR) <2.6, Mo 6
Kremer J, et al. EULAR 2011, London, #LB0005
BMS
India
BMS
India
Tofacitinib [Tofa] (oral JAK 3,1,2 inhibitor) incombination with traditional DMARDs (ORAL Sync)
5 mg BID 10 mg BID PBO5 mg PBO10 mgn=315 n=318 BID n=79 BID n=80
Tender joints (68), mean 25.0 26.6 27.2 21.9Swollen joints (66), mean 14.5 14.4 14.6 13.9HAQ-DI, mean 1.44 1.43 1.45 1.24DAS28-4(ESR), mean 6.29 6.36 6.44 6.16Prior DMARD useMTX, % 86.7 82.7 83.5 82.5
Other traditional DMARDs, % 73.7 76.1 69.6 77.5
TNFi, % 7.3 6.0 6.3 6.3Other Biologic DMARD use, % 2.2 3.1 7.6 0.0DispositionPatients completing, % 82.1 79.2 89.9 83.8D/C due to AE, % 6.4 9.1 2.5 3.8D/C due LOE, % 5.1 3.8 3.8 3.8
Kremer J, et al. EULAR 2011, London, #LB0005 78
BMS
India
BMS
India
Tofacitinib [Tofa] (oral JAK 3,1,2 inhibitor) in combination with traditional DMARDs (ORAL Sync)
ACR20 at Mo 6
PBO Tofa 5 mg Tofa 10 mg 70
60
50
40
30
20
10
0
* 52.7
31.2
* 58.3
*P<0.0001 vs PBO
Kremer J, et al. EULAR 2011, London, #LB0005
BMS
India
BMS
India
Tofacitinib [Tofa] (oral JAK 3,1,2 inhibitor) in combination with traditional DMARDs (ORAL Sync)
0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
HAQ-DI to Month 3
PBO
-0.21
-0.46 *
-0.56 *
Tofa 5 mg
16
14
12
10
8
6
4
2
0
DAS28<2.6 to Month 6
Tofa 10 mg * 14.8
* 11.0
2.7
*P<0.0001 vs PBO
Kremer J, et al. EULAR 2011, London, #LB0005
BMS
India
BMS
India
Tofacitinib [Tofa] (oral JAK 3,1,2 inhibitor) incombination with traditional DMARDs (ORAL Sync)
% Months 0-3 Months 3-6 Post Month 6
5 mg 10 mg 5 mg 10 mg PBO PBO 5 mg 10 mg PBO PBOBID BID PBO PBO BID BID 5 10 BID BID 5 10
n=315n=318n=159 n=81 n=315n=318 n=38 n=40 n=315n=318 n=79 n=80
SAE 2.9 2.5 3.8 0 1.6 2.2 0 0 2.2 2.8 2.5 0
SIE 0.6 1.2 0 0 0 0 0.3 0.3 1.0 2.5 0 0
D/C AE 4.1 4.1 1.3 1.2 1.9 2.5 0 2.5 0.3 2.8 0 1.3
Kremer J, et al. EULAR 2011, London, #LB0005
BMS
India
BMS
India
Tofacitinib [Tofa] (oral JAK 3,1,2 inhibitor) in combination with traditional DMARDs (ORAL Sync)
Month 3 Post Month 6
PBO 5 mg 10 mg PBO5 PBO10 5 mg 10 mg
Change from baseline (LS Mean)
ANC (103/mm3) -0.02 -0.75* -0.99* -0.72 -0.66 -0.79 -0.90
Hb (g/dL) -0.04 0.28 0.11 0.41 0.23 0.44 0.19
LDL (%) -0.61 15.65* 18.26* 7.72 12.85 16.24 19.93
Serum Cr (mg/dL) 0.02 0.03 0.06* 0.05 0.08 0.06 0.08
AST>1x ULN (%) 13.8 23.5 29.4 19.1 26.7 19.4 24.6
AST>3x ULN (%) <1.0 <1.0 <1.0 1.1 <1.0 0 1.4
ALT>1x ULN (%) 17.6 27.9 34.2 18.8 27.4 22.2 23.2
ALT>3x ULN (%) <1.0 1.9 <1.0 2.6 1.9 0 1.4
*P<0.0001 vs PBO
Kremer J, et al. EULAR 2011, London, #LB0005 82
BMS
India
BMS
India
Tofacitinib [Tofa] (oral JAK 3,1,2 inhibitor) in combination with traditional DMARDs (ORAL Sync)
4 deaths
• 81-year old man (US): Traumatic brain injury and intracranial hemorrhage following a fall 22 days after discontinuing 5 mg
• 37-year old man (China): Found dead on Day 174 of 10 mg - Cause of death: Acute heart failure due to valvular heart disease
• 48-year old man (Russia): Hospitalized for worsening RA; discontinued 5 mg at Day 292; died 42 days later - Cause of death: Infection by DSMB
• 58-year old man (US): Presented with DOE, CHF, anemia, renal insufficiency at Day 357 on 10 mg; developed progressive pulmonary infiltrates, respiratory failure and pulmonary hypertension resulting in death - Cause of death: Infection by DSMB
4 OIs: 1 disseminated H zoster; 1 cryptococcal pneumonia; 2 TB
Tofacitinib effective in combination with DMARDs Overall safety still being evaluated
Kremer J, et al. EULAR 2011, London, #LB0005
BMS
India
BMS
India
Can you correct the lipid elevations caused by Tofa? OL Tofa with or without blinded atorvastatin (A)
• Tofa 10 mg BID for 6 weeks, then randomized to A 10 mg QD vs PBO for 6 more weeks; 1° EP: % change in LDL-C Weeks 6-121
• Previous data suggests Tofa ↑LDL-C ≈ 25%2; A ↓LDL-C ≈ 26-37%3
Week 0 Week 6 Week 12n=111 n=97 n=92
Total chol: A (n=50) 185.6 229.5 (24%↑) 170.0 (26.0%↓)**PBO (n=47) 202.0 244.4 (21%↑) 250.0 (2.3%↑)
LDL-C: A (n=50) 109.1 126.0 (16%↑) 81.9 (35.3%↓)**
PBO (n=47) 118.0 140.0 (19 %↑) 148.1 (5.8%↑)
TGs: A (n=50) 99.5 109.0 (10%↑) 95.0 (14.7%↓)*
PBO (n=47) 102.0 109.0 (7%↑) 115.0 (5.5%↑)
HDL-C 50.5 66.6 (32%↑) ↑ no difference
Apo A1 135.5 164.5 ( 21%↑) ↑ no difference
Median LDL-C achieved in the ATP-III optimal target range (<100 mg/dL). Efficacy not diminished; similar safety
1. McInnes I, et al. EULAR 2011, London, #LB0003; 2. Kremer J, et al. Arth Rheum 2009;60(Supplement 10):1925;
*P<0.01; **P<0.0001
3. Atorvastatin US approved package labeling, June 2009BMS India
BMS
India
Tofacitinib (Tofa): Phase III monotherapy (ORAL Solo)¹
ACR20
100 PBO (n=122) Tofa 5 mg (n=243) Tofa 10 mg (n=245) All P<0.05 or P<0.0001 versus placebo except Tofa 5 mg with prior biologic
80
60
40
20
0
• Pfizer press release on X-ray progression: 10 mg but not 5 mg Tofa effective2
• 21 patients in Korea (Phase IIb mono): Significantly less progression than on DMARD controls3
Tofacitinib effective in multiple subgroups; DB X-ray data coming 1. Fleischmann R, et al. EULAR 2011, London, #SAT0243; 2. Pfizer Press Release April 15, 2011; 3. Choi IH, et al. EULAR 2011, London, #SAT0240
BMS
India
BMS
India
ORAL Solo: SF-36 domain scores at Month 3
Age/Gender Norms Tofa 10 mg BID (n=224) Tofa 5 mg BID (n=223) PBO (n=108) Composite (Weighted balance)
*P<0.05 **P<0.01 ***P<0.001
*P<0.0001 vs BL
* MHI **
* RE
* SF *
PF 90 80 70 60 50 40 30 20 10 0
VIT
*
RP * *
BP
GHP ** *
*
*
* *
Clinically meaningful improvements in ALL PROs Strand V, et al. EULAR 2011, London, #OP0063
BMS
India
BMS
India
Fostamatinib (Syk kinase inhibitor) and HRQOL: Phase II RCT • Pro-drug; currently in Phase III RCTs (OSKIRA trials) in RA1
• Phase II RCT: Syk vs PBO in MTX-IR RA at 6 mos2
- Pain (VAS); Patient global (VAS); HAQ-DI; SF-36, FACIT
Patient Reported Outcomes PBO Fostamatinibn=153 n=304
Mean ∆ from BL at Mo 6 150 mg QD 100 mg BID3
n=152 n=152SF-36 PCS 4.9 5.9 8.5**
SF-36 MCS 3.7 2.0 4.0FACIT-Fatigue 4.5 5.7 7.4*
*P<0.05; **P≤0.001
- Improvements at Week 1 in Pain and HAQ statistically significant in both Rx groups vs PBO; Patient global only in 100 mg BID; but not sustained
Improvement in PROs at 6 months only in PCS and FACIT with 100 mg BID
1. Baluom M,et al. EULAR 2011, London, #SAT0247; 2. Weinblatt ME, et al. NEJM 2010;363:1303-12; 3. Weinblatt, ME et al. EULAR 2011, London, #OP0057
BMS
India
BMS
India
Tocilizumab in the US (ACT-STAR)
• 24-week OL study
• DMARD or DMARD + Bio IR at BL • TCZ 4 mg/kg + DMARD
• TCZ 8 mg/kg + DMARD - Biologic-IR alone at BL
• TCZ 8 mg/kg monotherapy • 3 GI perforations:
- 1 Crohn's, 2 diverticulitis (subsequently diagnosed)
• 21% on statins at BL, 11% added statins during the study
• 42% TCZ 4 mg/kg + DMARD maintained to Month 6
% Patients
SAE
SAE → D/C
Deaths (n)
SIE
PMNs (Gr 3)
ALT: 1.5-3x ULN
>3x ULN
LDL-C ≥130 (<130 at BL)
TCZ 4/8 TCZ 8 +DMARD +DMARD
n=364 n=381
8.0 8.4 3.0 1.0 2 0
3.6 3.9 0.8 2.4 7.9 13.2
2.1 1.4
16.8 17.7
TCZ 8
n=138
5.8 2.2 0
2.9 5.1 6.1
1.5
11.7
No difference in SAE, SIE or efficacy between COMBO & MONO TCZIs 4 mg/kg really safer than 8 mg/kg?
Weinblatt ME, et al. EULAR 2011, London, #LB0006
BMS
India
BMS
India
ACT-STAR: Patient Disposition
Patients enrolled (N=886)
Randomized to TCZ 4 mg/kg* + DMARD
n=363**
Switched to TCZ 8 at Week 8
n=142 (39.2%)
Switched to TCZ 8 after Week 8 n=68 (18.8%)
Only exposed to TCZ 4
n=152 (42.0%)
Completed study, n=303 Withdrew, n=60
(35 safety / 25 non-safety)
Randomized to TCZ 8 mg/kg + DMARD
n=360
Completed study n=302
Withdrew n=58
Safety n=17
Non-safety n=41
Assigned to TCZ 8 mg/kg monotherapy
n=163
Completed study n=126
Withdrew n=37
Safety n=11
Non-safety n=26
*Patients randomized to TCZ 4 + DMARD may have withdrawn prior to Week 8 while still receiving TCZ 4, or afterWeek 8 while receiving TCZ 4 or TCZ 8; **1 patient randomized did not receive drug
Weinblatt ME, et al. EULAR 2011, London, #LB0006
BMS
India
BMS
India
Tocilizumab: Long-term safety in RCT
• LTE; 4,009 pts (median treatment duration 3.6 ys); 12,293 pt-ys (to 02/2010)
• Most patients on 8 mg/kg q month
Event rate/100 pt-ys (95% CI) over 12-month periods
0-12 13-24 25-36 37-48 Overall
SAE 15.7 (14.4, 17.1) 13.9 (12.6, 15.2) 15.2 (13.7, 16.7) 14.4 (12.8, 16.0) 14.7 (14.0,15.4)
SIE 4.6 (3.9, 5.4) 3.9 (3.2, 4.7) 5.2 (4.3, 6.1) 4.9 (4.0, 5.9) 4.6 (4.3, 5.0)
CVA 0.3 (0.1, 0.5) 0.1 (0.0, 0.3) 0.2 (0.1, 0.4) 0.1 (0.0, 0.3) 0.2 (0.1,0.3)
MI 0.3 (0.1, 0.5) 0.2 (0.1, 0.4) 0.3 (0.1, 0.6) 0.5 (0.3, 0.9) 0.3 (0.2, 0.4)
• Most common AEs leading to discontinuation: Laboratory abnormalities- 1.1/100 pt-ys, transaminase elevations
• GI perforations 0.24/100 pt-ys; RA background rate 0.17/100 pt-ys
Stable rates of SAE, SIE and CV events over 4 years
Genovese M, et al. EULAR 2011, London, #SAT0270
BMS
India
BMS
India
In MTX-IR patients is it better to add TCZ or switch to TCZ? (ACT-RAY)
• 2-year RCT - 24-week data - Biologic-naive
Endpoint (%) TCZ 8 TCZ 8 +MTX +PBO n=277 n=276
- 8.2 ys disease DAS28<2.6 40.4 34.8
- DAS28(ESR)=6.35 (median) LDAS 61.7 51.4*
- TCZ 8 mg/kg q 4 weeks ACR20 71.8 70.7• 1º EP: DAS≤2.6 ACR70 24.9 25.7
• Other than LFTs, safety data no difference
LFT abnormalities (%)
1.5-3x ULN 8.5 4.4
>3-5x ULN 1.7 0.4
*P=0.028Efficacy equal whether switch or add.Do you want to switch rather than add?
Dougados M, et al. EULAR 2011, London, #OP0020
BMS
India
BMS
India
aIL-6 mAb in MTX-IR
• Asialated mAb to IL-6 NOT IL-6R
• 80, 160, 320 mg vs PBO, 100
IV+MTX q 8 wks1
Responders (%) 1°EP: Week 12 ACR and LDAS
ACR20 ACR50 ACR70 LDAS
*P<0.05
• T½ = 30 days 80
• SC vs IV dosing:2 60
- Bioavailability of ALD518 ≈ 60% for SC vs IV dosing
40
- Rapid, sustained reductions in serum CRP all doses, IV or SC 20
• Phase III with SC dosing
0
27
9 3
* 81
* 71
27 21
12 7
* 82
* 50
* 34 33
* 25
13
46
PBO (n=33) 80 mg (n=32) 160 mg (n=34) 320 mg (n=28)
Positive proof of concept at Week 12
1. Mease P, et al. ACR 2010, Atlanta, #2168;2. Shakib S, et al. EULAR 2011, London, #SAT0296
BMS India
BMS
India
aIL-6 mAb and HRQOL: SC in Phase III RCTs
- -PF Combined BL 90
80 Age/Gender Norms ‡ * 70 ‡ PBO+MTX n=30
80 mg+MTX n=29 160 mg+MTX n=33 320 mg+MTX n=26
*P< 0.05 †P<0.05 ‡P<0.05 ‡ *
• SC dosing planned in Phase III RCTs
H
E
60
50
40
30
20
10
0
R
* ‡ B
Mean changes in SF-36 domains support dose selection ‡ * F G * ‡and benefit of 320 mg
V *† ‡Strand V, et al. EULAR 2011, London, #SAT0304;Shakib et al, Ibid, #SAT0296
BMS
India
BMS
India
Other aIL-6 mAbs in development
• CNTO 136: POC in Phase II RCT in DMARD-IR:1
- Part 1: 100 mg SC q 2 weeks x5 well tolerated; interim analysis at Week 12 - ACR20: 21% vs 75% (P=0.002); DAS28(CRP) -0.65 vs -1.66 (P=0.001); good/moderate EULAR: 11%/21% vs 38%/44% (P=0.015) in active group ACR components (P<0.05 for all, except patient pain) - 1 SAE: staphylococcal cellulitis in active - ↓PMNs; ↑ALT; ↑cholesterol in 2/14 PBO vs 3/5 active - Part 2: Dose-ranging
• CDP6038: Single dose IV and SC administration in 67 healthy volunteers:2
- Selectively blocks final assembly step of IL-6 signaling complex - PK, PD after IV [0.001-10.0 mg/kg] and SC [0.3, 1.0 or 3.0 mg/kg] dosing - TEAE higher with PBO vs active: 52.9% vs 33.3%: ‟flu, diarrhea, URI - ↓PMN; WBC counts and ↑ALT without dose dependency; no ∆ in lipids - Median T½ = 31.1 days IV and SC; independent of dose
1. Hsu B, et al. EULAR 2011, London, #FRI0345; 2. Hickling M, et al. Ibid, #FRI0378
BMS
India
BMS
India
Rituximab long-term safety in RCTs
Incidence per 100 pt-ys
• RTX vs PBO:
• Up to 9.5 years follow-up
• Up to 17 courses of RTX
• RTX 500/1000 mg x 2
• AE, SAE/100 pt-ys: Similar, courses 1-6
• Malignancy SIR: 0.99 vs SEER
Pt-ys
AE SAE
Infection SIE
PBO All RTX n=818 n=3,194
1,107 11,962
315 263 14 14
90 82 3.8 3.9
>5 ys RTX n=627
4,418
254 14
75 3.3
SOI 0.09 0.06 NR
NR, not reported
RTX safety appears to be stable from course to course and overtime in patients who remain in LTE studies
van Vollenhoven RF, et al. EULAR 2011, London, #SAT0267
BMS
India
BMS
India
Rituximab potpourri
• B-cell count at Week 26 may predict subsequent response to RTX1
- Absence of B-cells at Week 26: 100% stable/improving DAS28 at Week 40
- Presence of B-cells at Week 26: 45% worse DAS28 at Week 40
• Impaired response to pneumococcal vaccination with RTX2
- RTX and MTX (not TNF-IR) associated with impaired antibody response following vaccination with heptavalent pneumococcal conjugate vaccine
• JCPyV infections in RTX-treated patients3
- 38% of RTX-treated patients with multiple tests for JCPyV DNA had virus in urine (generally reported at approximately >75% in the normal population4)
- Isolates belonged to different genotypes not associated with PML
• Patients treated with the addition of RTX to a biologic over 26 weeks5
- SIE 1.7% vs 1.9% in REFLEX; only 42.6% EULAR moderate/good response
1. Vital E, et al. EULAR 2011, London #OP0012; 2. Kapetanovic MC, et al. Ibid, #OP00163; 3. Verheyen J, et al. Ibid, #SAT0268; 4. Walker DL, Padgett BL Prog Clin Biol Res 1983;105:99-106; 5. Rigby W, et al. EULAR 2011, London, #SAT0308
BMS
India
BMS
India
Ofatumumab (OFA), a fully human aCD20 mAb, in biologic-naive RA • Phase III double-blind vs PBO1
• MTX-IR; mean 8.5 ys disease
• 700 mg OFA at Weeks 0 and 2, + 100 mg IV MP
• 1º EP: ACR20 at Week 24
• Safety - No immunogenicity - Rash (21%); urticaria (12%) vs
<1% PBO
• SC in development without steroid pre-treatment2
ACR20 ACR50
60 ** 50
50
40
30 27
20
11 10
2 0
PBO n=131
ACR70
** 27
* 13
OFA n=129
Small delta in ACR responses; SC in development*P<0.01; **P<0.001
1. Taylor PC, et al. EULAR 2011, London, #OP0019;2. Kurrasch R, et al. Ibid, #SAT0288
BMS
India
BMS
India
Anti-BAFF mAb in RA1
80
70
60
50
40
30
20
10
0
ACR20 ACR50
61
47 44 45
40
33
22
10 10 11
PBO 1 3 10 30
LY mg
• 7*
• 54
•
38 •
•
8
•
60 120 •
Human mAb; neutralizes membrane-bound and soluble BAFF
156 MTX-IR; active RA
LY 1, 3, 10, 30, 60,120 mg SC q 4 wks x6
1° EP: Dose response of ACR50
Safety:
- SAE: 10% LY vs 11.1% PBO
- SIE: 2.5% LY vs 0% PBO
Decreases in mean IgM and IgA at higher
LY doses: Not associated with infections
Study with LY IV Q 3 weeks X3 at 30 or 80 *P<0.05 vs PBO (one-sided Fisher‟s exact test) mg vs PBO in TNF-IR; ACR50 at Wk 16 as
1° EP, not statistically different2
Anti-BAFF mAb, at these doses and frequency, not effective in RA 1. Genovese M, et al. EULAR 2011, London, #OP0017; 2. Genovese M, et al. Ibid, #SAT0275
BMS
India
BMS
India
Safety of SC abatacept in patients with RA: Analysis of five RCTs ≤4.5 years
• Exposure (SC)1
- 1,879 patients - 3,086 pt-ys - 1,191 (63%) treated >18 mos - Mean duration of treatment
20 mos (range: 2-56)
• Exposure (IV)2
- 4,149 patients - 12,132 pt-ys - 1,165 (28%) treated ≥5 ys - Mean duration of treatment
36 mos (range: 2-104)
Safety SC ≈ IV abatacept
1. Alten R, et al. EULAR 2011, London, #SAT0292;
Incidence rates: Events/100 pt-ys
Deaths
SAEs
Serious infections
SIEs
Pneumonia
Lobar pneumonia
Herpes zoster
TB
SC ABA IV ABA 125 mg/wk 10 mg/kg
0.55 0.60 (0.34-0.89) (0.47-0.76)
9.53 14.61 (8.46-10.72) (13.85-15.41)
1.94 2.87 (1.50-2.50) (2.57-3.19)
0.36 0.46 (0.20-0.65) (0.34-0.59)
0.10 0.11 (0.03-0.30) (0.06-0.18)
0.10 0.03 (0.03-0.30) (0.01-0.08)
0.03 0.03 (0.00-0.23) (0.00-0.23)
2. Hochberg MC, et al. ACR 2010, Atlanta, #390
BMS India
BMS
India
Does SC abatacept require IV loading?
• Comparison of two Phase III trials, with or without IV loading1
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
•
HAQ-DI
Baseline Month 3
1.4 1.3
1.1
0.7
IV loading (n=167) No IV loading (n=100)
Similar Cmin in both studies2
6.0
5.0
4.0
3.0
2.0
1.0
0.0
DAS(CRP)
Baseline Month 3
5.4
4.7
3.8
3.2
IV loading (n=167) No IV loading (n=100)
Not head-to-head; IV probably not needed
1. Nash P, et al. EULAR 2011, London, #SAT0287;2. Murphy, B et al. Ibid, #FRI0346
BMS
India
BMS
India
Abatacept potpourri
• One can effectively and safely switch from IV to SC1
• IV vs SC in a head-to-head is equal in efficacy2
• Subset analysis of fixed dose of ABA SC vs IV for weight and disease duration have equal benefits and similar safety3
• It appears that we can effectively and safely start and stop SC ABA3
1. Keystone E, et al. EULAR 2011, London, #FRI0351; 2. Genovese M, et al. Ibid, #OP0023; 3. Kaine JL, et al. Ibid, #FRI0366
BMS
India
BMS
India
Abatacept & tocilizumab in routine care (DANBIO)
• ABA (n=150), TCZ (n=178) - almost all after first biologic
DAS28 variables: Time since treatment initiation (weeks) 6 14
Abatacept
• 48-week results
• Drug survival: - ABA 50% - TCZ 60%
• DAS28(CRP) remission: - ABA 26% (n=38) - TCZ 58% (n=19)
• EULAR good/moderate: - ABA 77% - TCZ 84%
5
4
3
2
1
0 0 6 12
24
80 70
60
50
40
30
20
10
0 0 6 12 24
Abatacept
Tocilizumab
36 48
Abatacept
Tocilizumab
36 48
12
10
8
6
4
2
0 0 6 12 24
20
18 16
14 12
10 8 6 4
2 0
0 6 12 24
Tocilizumab
36 48
Abatacept
Tocilizumab
36 48
In TNF-IR, 2/3 of ABA, TCZ survive to 48 weeks
Leffers HC, et al. EULAR 2011, London, #FRI0358
BMS
India
BMS
India
Abatacept & rituximab use after malignancy: AIR & ORA registries
• Prospective 5-yr registries - AIR = RTX; n=2,000 - ORA = ABA; n=1,000
• History of cancer - 268 RTX (13.6%) – 54 ABA (5.4%)
• Most common cancer: Breast
• Median duration after cancer to first infusion - RTX 4 ys - ABA 7 ys
• 191/268 RTX, 41/54 ABA had follow-up
Death
New cancer
New metastasis
Severe infection
ABA
1 (infection)
1
1
7.4%
RTX
5 (cancer)
3
6 (18 mos after 1st infusion)
7.1%
Is it really preferable to use rituximab vs other biologics in patientswith previous cancer?
Gottenberg JE, et al. EULAR 2011, London, #FRI0363
BMS
India
BMS
India
Drug retention in TNF-IR: 2nd TNFi or ABA/RTX/TCZ • Swiss RA cohort SCQM-RA;
1,497 biologic courses in TNF-IR - 858 2nd TNF – 629 non-TNF biologic
• Total of 2,142 pt-ys on biologics - Higher GC and MTX in TNF group
- Prior TNFs: 2.7 TNF group vs 2.0 non-TNF group
• Drug retention: - 2nd TNF vs non-TNF:
Adjusted HR 2.12 (1.74-2.6)
• Median survival time - 2nd TNF = 21 mos (IQR 8-53)
– Non-TNF = 32 mos (IQR 14-64)
• Reasons for discontinuation unknown
Time to discontinuation of biologic agents
100
Other BIO 80 Anti-TNF
60
40
20 P<0.001
0
0 1 2 3 4 5 Time (year)
Swiss conclude: After first TNF, non-TNF biologics are better;do you agree?
Martin-du-Pan Prujim S, et al. EULAR 2011, London, #SAT0298
BMS
India
BMS
India
Not ready for prime time
• Oral S1P lyase inhibitor LX3305: Failed in Phase II to show efficacy in MTX IR in RA with a good safety profile
- Higher doses will be explored in a further IB study for efficacy and safety¹
• IL-10 producing T-reg 1 cells: In human serum in patients with severe RA, migration to synovium and suppressive capacity demonstrated2
• Anti-lymphotoxin mAb: Phase I RCT in DMARD-IR RA: SAD, MAD: 3 mg/kg q 2 wks x 3: at Week 6 preliminary efficacy; linear PK, biologic effect: ↓↓ CXCL-13 demonstrated with acceptable safety; not POC3
• Rheumavax: Autologous tolerizing dendritic cells exposed to citrullinated peptides: Phase I in 18 DR+ACPA+DMARD-IR RA vs 11 controls [OL]4:
- 7 maintained DAS<2.6 over 6 mos; 6 attained DAS<2.6 for 3-6 mos; 5: NR– 9 controls: NR; 2: DAS ↓
1. Fleischmann R, et al. EULAR 2011, London, #OP0059;2. Asnagli H, et al. Ibid, #OP0119;3. Emu B, et al. Ibid, #OP0018;4. Thomas R, et al. Ibid, #LB0004
BMS
India
BMS
India